社区获得性肺炎患者抗菌药物应用情况分析

Abstract
Figure/Table
References (20)
Related Citation (10)

Download: PDF (436 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application situations of antibacterial agents in patients with community-acquired pneumonia (CAP) in Zhujiajiao People′s Hospital of Qingpu District in Shanghai City (“our hospital” for short), so as to improve the rationality of clinical application of antibacterial agents. Methods The medical history of patients diagnosed as CAP in all medical records of our hospital from January 2016 to June 2017 was summarized retrospectively. The type of antibacterial agents, frequency, drug combination, course of treatment, therapeutic effect and so on were analyzed statistically, the drug utilization index (DUI) was used as judging indicator of drug use. Results Among the antibacterial agents of CAP treatment in our hospital, the top three of use frequency was cephalosporins, fluoroquinolones and penicillins, the most widely-used was Cefotiam, all was in double combinations, the most common was combination of cephalosporins and fluoroquinolones [14 cases (33.33%)], the course was (5.28±3.83) d. Among 153 cases of patients, 50 cases (32.68%) were cured, 98 cases (64.05%) were improved, 2 cases (1.31%) were not healed, 3 cases (1.96%) were discharged or transferred. There were 4 kinds (26.67%) of antibacterial agents with DUI ranged from 0.9 to 1.1, 3 kinds (20.00%) of antibacterial agents with DUI＜0.9, 8 kinds (53.33%) of antibacterial agents with DUI＞1.1. Conclusion The total application situations of antibacterial agents in patients with CAP in our hospital are basically reasonable, but there are still some disadvantages and the drug use still needs further standardized.

Key words： Community-acquired pneumonia Antibacterial agents Rational drug use

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHENG Chunqin1 ZHU Jingjie1 FENG Tingting2

Cite this article:

SHENG Chunqin1 ZHU Jingjie1 FENG Tingting2. Analysis on the application situations of antibacterial agents in patients with community-acquired pneumonia[J]. 中国医药导报, 2018, 15(5): 136-139.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I5/136

[1] Lozano R，Naghavi M，Foreman K，et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010：a systematic analysis for the Global Burden of Disease Study 2010 [J]. Lancet，2012，380（9859）：2095-2128.
[2] Song JH，Thamlikitkul V，Hsueh PR. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia Pacific region [J]. Int J Antimicrob Agents，2011，38（2）：108-117.
[3] 中华医学会呼吸病学分会.中国成人社区获得性肺炎诊断和治疗指南（2016年版）[J].中华结核和呼吸杂志，2016， 39（4）：253-279.
[4] 袁孔现，李顺炜，李国忠.我院门诊患者抗感染药物使用分析[J].安徽医药，2005，9（3）：213-214.
[5] Niederman MS，Mandell LA，Anzueto A，et al. Guidelines for the management of adults with community-acquired pneumonia，Diagnosis，assessment of severity，antimicrobial therapy，and prevention [J]. Am J Respir Crit Care Med，2001，163（7）：1730-1754.
[6] Mandell LA，Wunderink RG，Anzueto A，et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults [J]. Glin Infect Dis，2007， 44（Suppl2）：S27-S72.
[7] British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults [J]. Thorax，2001，56 Suppl 4：Ⅳ1-Ⅳ64.
[8] Sun T，Sun L，Wang R，et al. Clinical efficacy and safety of moxifloxacin versus levofloxacin for community- acquired pneumonia with aspiration factors [J]. Chin Med J，2014， 127（7）：1201-1205.
[9] Kuzman I，Bezlepko A，Kondova Topuzovska I，et al. Efficacy and safety of moxifloxacin in community acquired pneumonia：A prospective，muhicenter，observational study [J]. BMC Pulm Med，2014，14（1）：105.
[10] Moran GJ，Rothman RE，Volturo GA. Emergency management of community acquired bacterial pneumonia：what is new since the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines [J]. Am J Emerg Med，2013，31（3）：602-612.
[11] 鞠学贵.社区获得性肺炎首剂抗生素治疗最佳时机的研究进展[J].四川解剖学杂志，2014，22（4）：23-26.
[12] Mandel LA，Bartlett JG，Dowel SF，et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults [J]. Clin Infect Dis，2003，37（11）：1405-1433.
[13] NICE. National institute for health and clinical excellence，Diagnosis and management of community and hospital acquired pneumonia in adults [J]. Britist Med J，2014， 349：S1-S27.
[14] 陈冬梅，冯杏凤.社区获得性肺炎患者抗菌药物应用分析[J].中国药物经济学，2015（7）：18-20.
[15] 邓紫薇，仇成凤，李茂作，等.成人社区获得性肺炎主要病原体分布的Meta分析[J].中国抗生素杂志，2016，41（12）：950-955.
[16] 范柏.喹诺酮类抗菌药的作用机制及细菌耐药性的研究进展[J].国外医药：抗生素分册，2004，25（1）：27-29.
[17] 宋晓宏.76例大肠埃希菌尿路感染分析[J].安徽医药，2004，8（6）：444-445.
[18] 宋宇，刘晓民.不同年龄社区获得性肺炎危险因素分析[J].哈尔滨医科大学学报，2016，50（4）：362-365.
[19] Ewig S，Klapdor B，Pletz MW，et al. Nursing-home-acquired pneumonia in Germany：an 8-year prospective muhicentre study [J]. Thorax，2012，67（2）：132-138.
[20] 马文通，张泓.CURB-65评分和强化CURB评分对老年重症社区获得性肺炎预测价值的临床研究[J].中国急救医学，2016，36（3）：238-241.